A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » IAS 2011

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Life Expectancy for Young People With HIV Is Nearly Normal
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
Scientists Devise Method of Snipping HIV From Immune Cells
Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV
FDA Approves New Single-Tablet HIV Regimen, Triumeq
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

July 21, 2011

Edurant and Sustiva Similar, With Some Failure and Safety Differences, in Two-Year Studies

by Tim Horn

The efficacy of Janssen Therapeutics’ Edurant (rilpivirine) is similar to that of Sustiva (efavirenz) over two years of treatment, according to an analysis of two large clinical trials, but Edurant demonstrated much fewer central nervous system side effects, according to a presentation Tuesday, July 19, at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome.

Edurant was approved by the U.S. Food and Drug Administration (FDA) in May 2011. Forty-eight week data from two Phase III clinical trials—ECHO and THRIVE—were used to support the drug’s approval application.

Final, long-term follow-up data from the studies, reflecting 96 weeks (nearly two years) of observation, were reported at IAS 2011 by Calvin Cohen, MD, from the Community Research Initiative New England, in Boston.

ECHO was a 690-person study comparing 25 mg of Edurant once-daily plus Truvada (tenofovir plus emtricitabine) with Sustiva plus Truvada for 96 weeks in first-time treatment-takers. The THRIVE study, with 678 participants, had a similar design, but people were able to use Epzicom (abacavir plus lamivudine) or Combivir (zidovudine plus lamivudine) instead of Truvada.

To be enrolled in either study, people had to have a viral load of 5,000 or higher, no resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), and full sensitivity to Truvada, Epzicom or Combivir. Characteristics of the participants were similar in both studies, with participants having an average CD4 count of roughly 250 and with about half of the participants having a viral load over 100,000 copies.

Cohen reported that Edurant efficacy was statistically similar in both studies compared with Sustiva. In an analysis where the two studies were pooled together, 77.6 percent of those taking Edurant or Sustiva had a viral load of less than 50 copies at week 96.

Virologic failures—defined as either an inability to reduce viral load to undetectable levels or a rebound in viral load after achieving an undetectable result—were nearly twice as likely among those receiving Edurant compared with Sustiva, occurring in 14 percent and 7.6 percent, respectively. Cohen noted, however, that the difference between the two groups was only notable during the first 48 weeks of treatment; virologic failures generally occurred at the same rate during the second half of the study.

The development of NNRTI-associated resistance mutations occurred equally among those in the two groups—57 percent of those taking Edurant who experienced virologic failure and 54 percent of those taking Sustiva who experienced virologic failure. However, the development of mutations conferring resistance to nucleoside reverse transcriptase inhibitors—notably the M184 mutation known to decrease sensitivity to lamivudine and emtricitabine—was more likely to occur among those who experienced virologic failure while taking Edurant compared with Sustiva (56 percent versus 31 percent, respectively).

Cohen noted that most patients who had NNRTI-associated resistance mutations upon experiencing virologic failure while on Edurant had the E138K mutation, which can hinder the effectiveness of Edurant, a second-line NNRTI option. Encouragingly, no participants developed the K103N mutation, which means that they may benefit from using Sustiva in subsequent regimens. 

Among those in the Sustiva group who had NNRTI-associated resistance mutations and who experienced virologic failure, K103N commonly arose, whereas E138K did not.

In terms of tolerability and side effects, Edurant performed much better than Sustiva. In fact, side effects leading to discontinuation of therapy were more than twice as common among those taking Sustiva compared with Edurant (8.5 percent versus 4.1 percent, respectively). And across the board, moderate-to-severe adverse events were twice as likely among Sustiva takers compared with Edurant takers (33 percent versus 17 percent, respectively).

Central nervous system problems, such as abnormal dreams and dizziness, as well as rash, were more likely to occur among those taking Sustiva compared with Edurant.
There was also a trend toward higher rates of moderate-to-severe total cholesterol levels, “bad” LDL cholesterol levels and triglyceride levels among those taking Sustiva compared with Edurant.

Cohen concluded by pointing out the high response rate in both groups and the similarity in efficacy between Edurant and Sustiva, while also acknowledging the higher rate of virologic failures in the Edurant group and the higher rate of treatment-related adverse events in the Sustiva group. He also noted that Janssen continues to work with Gilead Sciences on the development of a single, once-daily pill combining both Edurant and the two active drugs in Truvada.

Search: Edurant, rilpivirine, Sustiva, efavirenz, ECHO, THRIVE, efficacy, failure, treatment-naive, Cohen, IAS, Rome


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    CuteBoyinQns
    Jackson Heights
    New York


    july8th69
    brooklyn
    New York


    TaintedloveDC
    Washington
    DC


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.